Mueller, R. B., Spaeth, M., von Restorff, C., Ackermann, C., Schulze-Koops, H., & von Kempis, J. (2019). Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. J Clin Med.

Mueller, Ruediger B., Michael Spaeth, Cord von Restorff, Christoph Ackermann, Hendrik Schulze-Koops, och Johannes von Kempis. "Superiority of a Treat-to-Target Strategy Over Conventional Treatment With Fixed CsDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients With an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy With Certolizumab Pegol." J Clin Med 2019.

Mueller, Ruediger B., et al. "Superiority of a Treat-to-Target Strategy Over Conventional Treatment With Fixed CsDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients With an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy With Certolizumab Pegol." J Clin Med 2019.